ArticleEmerging infectious diseases2019
Epidemiologic Shift in Candidemia Driven by Candida auris, South Africa, 2016-2017
Article in Emerging infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 3 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Candida auris-a systematic review to inform the world health organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Candida parapsilosis: A systematic review to inform the World Health Organization fungal priority pathogens list.Medical mycology · 2024Pooled it
- Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris.BMC infectious diseases · 2020Pooled it
- Pathogenicity and virulence ofVirulence · 2026Review
- 30-day mortality and antifungal resistance in confirmed Candida auris bloodstream infections (BSI): a systematic review and meta-analysis.Infection · 2026Review
- Contemporary Trends in Candidemia: Mortality, Species, and Antifungal Resistance Across Three Periods (2017-2025) in Houston, Texas.Open forum infectious diseases · 2026Article
- Review
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa.Emerging infectious diseases · 2026Article
- Phage Display-Derived Peptides Have Neutralizing Activities Against Biofilm Formation byPharmaceuticals (Basel, Switzerland) · 2026Article
- Prevalence, pattern of disease and antimicrobial susceptibility ofSouthern African journal of infectious diseases · 2026Article
- Name changes for fungi of medical importance, 2022-2024.Journal of clinical microbiology · 2025Review
- Recent Systemic Antifungal Exposure and Nonsusceptible Candida in Hospitalized Patients, South Africa, 2012-2017.Emerging infectious diseases · 2025Article
- ManagingAntimicrobial agents and chemotherapy · 2025Article
- Yeast fungaemia among injection drug users in France (2012-2022): a cross-sectional observational study.The Lancet regional health. Europe · 2025Article
- The Burden of Neonatal Invasive Candidiasis in Low- and Middle-income Countries: A Systematic Review and Meta-analysis.Open forum infectious diseases · 2025Article
- Genetic Epidemiology and Resistance Investigations of Clinical Yeasts in Alexandria, Egypt.Pathogens (Basel, Switzerland) · 2025Article
- Antifungal stewardship in the UK: where are we now?JAC-antimicrobial resistance · 2025Article
- Article
- Risk Factors forInfection and drug resistance · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida auris is an invasive healthcare-associated fungal pathogen. Cases of candidemia, defined as illness in patients with Candida cultured from blood, were detected through national laboratory-based surveillance in South Africa during 2016-2017. We identified viable isolates by using mass spectrometry and sequencing. Among 6,669 cases (5,876 with species identification) from 269 hospitals, 794 (14%) were caused by C. auris. The incidence risk for all candidemia at 133 hospitals was 83.8 (95% CI 81.2-86.4) cases/100,000 admissions. Prior systemic antifungal drug therapy was associated with a 40% increased adjusted odds of C. auris fungemia compared with bloodstream infection caused by other Candida species (adjusted odds ratio 1.4 [95% CI 0.8-2.3]). The crude in-hospital case-fatality ratio did not differ between Candida species and was 45% for C. auris candidemia, compared with 43% for non-C. auris candidemia. C. auris has caused a major epidemiologic shift in candidemia in South Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.